Cancer Immunotherapy

被引：5
作者：
Bergman, Philip J. [1 ,2 ]
机构：
[1] BrightHeart Vet Ctr, Armonk, NY 10504 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
来源：
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE | 2010年 / 40卷 / 03期
关键词：
Cancer; Vaccine; Immunotherapy; Tumor; ENCAPSULATED MURAMYL TRIPEPTIDE; REGULATORY T-CELLS; SPONTANEOUS CANINE MELANOMA; COLONY-STIMULATING FACTOR; BIOLOGICAL RESPONSE MODIFIERS; RECOMBINANT FELINE INTERFERON; MEDIATED IMMUNE-RESPONSES; IMIQUIMOD 5-PERCENT CREAM; BACILLUS-CALMETTE-GUERIN; SOFT-TISSUE SARCOMA;
D O I：
10.1016/j.cvsm.2010.01.002
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
The veterinary oncology profession is uniquely able to contribute to the many advances that are imminent in immunotherapy. However, what works in a mouse will often not reflect the outcome in human patients with cancer. Therefore, comparative immunotherapy studies using veterinary patients may be better able to bridge murine and human studies. Many cancers in dogs and cats seem to be stronger models for their counterpart human tumors than presently available murine model systems. This author looks forward to the time when immunotherapy plays a significant role in the treatment and/or prevention of cancer in human and veterinary patients.
引用
收藏
页码：507 / +
页数：13
相关论文
共 100 条
[41]   Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma [J].
Kamstock, Debra ;
Elmslie, Robyn ;
Thamm, Douglas ;
Dow, Steven .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) :1299-1309
[42]  
Khanna C, 1997, CANCER-AM CANCER SOC, V79, P1409, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO
[43]  
2-3
[44]  
Khanna C, 1996, CLIN CANCER RES, V2, P721
[45]   Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer Patients [J].
Khanna, Chand ;
London, Cheryl ;
Vail, David ;
Mazcko, Christina ;
Hirschfeld, Steven .
CLINICAL CANCER RESEARCH, 2009, 15 (18) :5671-5677
[46]  
KLEIN W R, 1991, In Vivo (Attiki), V5, P605
[47]   PHASE-II STUDY OF LIPOSOMAL MURAMYL TRIPEPTIDE IN OSTEOSARCOMA - THE CYTOKINE CASCADE AND MONOCYTE ACTIVATION FOLLOWING ADMINISTRATION [J].
KLEINERMAN, ES ;
JIA, SF ;
GRIFFIN, J ;
SEIBEL, NL ;
BENJAMIN, RS ;
JAFFE, N .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1310-1316
[48]   Biological response modifiers: Interferons, interleukins, recombinant products, liposomal products [J].
Kruth, SA .
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 1998, 28 (02) :269-+
[49]  
Kuntsi-Vaattovaara H, 2003, Vet Comp Oncol, V1, P57, DOI 10.1046/j.1476-5829.2003.00005.x
[50]  
Kurzman ID, 1995, CLIN CANCER RES, V1, P1595
12345678910